Albert Labs has announced the appointment of new experts to both its clinical and scientific advisory boards.
The Canadian psychedelic drug developer’s boards will support the company's efforts to develop its proprietary psychedelics-based medicine and conduct accelerated studies on UK patients suffering from cancer-related anxiety.
The additions to the clinical advisory board, chaired by professor Jo Neill, bring expertise in psychology, psychiatry, palliative care and oncology. This multidisciplinary team will provide unrivalled guidance, helping Albert Labs progress through its accelerated Real-World Evidence (RWE) trial programme commencing in the UK later this year.
READ: Albert Labs going public soon as ME Resource submits listing statement to the Canadian Stock Exchange
The clinical board now includes the following professors and doctors: Jo Neill, Sara Tai, Sara Tookey, Sam Ahmedzai and Saoirse O'Sullivan.
On the scientific side, the new members, Naeem Khan and Denzil Phillips offer expertise in IP protection and development of novel manufacturing technologies through natural cultivation, extraction, formulation and delivery.
Their addition will be instrumental in allowing Albert Labs to develop and protect its pharmaceutical-grade natural psilocybin-based medicine.
Aside from the new appointments, Albert Labs has submitted applications to Health Canada for psychedelic research as well as a dealer's license which will allow the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline in its lab in Burnaby, BC Canada.
Once attained, these licenses will allow Albert Labs to export, test, and conduct R&D on these controlled substances.
Presently, Albert Labs is a private corporation, however it has applied to trade on the Canadian Security Exchange (CSE). Once approved the company will list under its current name, Albert Labs Inc and maintain its business as currently constituted.
Contact the writer at georgia@proactiveinvestors.com
Follow her on Twitter @MissInformd